The effects of canagliflozin compared to sitagliptin on cardiorespiratory fitness in type 2 diabetes mellitus and heart failure with reduced ejection fraction: The CANA-HF study.
Carbone S, Billingsley HE, Canada JM, Bressi E, Rotelli B, Kadariya D, Dixon DL, Markley R, Trankle CR, Cooke R, Rao K, B Shah K, Medina de Chazal H, Chiabrando JG, Vecchié A, Dell M, L Mihalick V, Bogaev R, Hart L, Van Tassell BW, Arena R, Celi FS, Abbate A.
Carbone S, et al. Among authors: trankle cr.
Diabetes Metab Res Rev. 2020 Nov;36(8):e3335. doi: 10.1002/dmrr.3335. Epub 2020 Jun 15.
Diabetes Metab Res Rev. 2020.
PMID: 32415802
Free PMC article.
Clinical Trial.